<DOC>
	<DOCNO>NCT01772953</DOCNO>
	<brief_summary>This prospective , open-label , nonrandomized , prospective clinical trial evaluate fix regimen treosulfan , fludarabine low-dose total body irradiation ( TBI ) child acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) undergo allogeneic hematopoietic cell transplantation ( HCT ) . The primary hypothesis HCT preparative regimen consist treosulfan , fludarabine low-dose TBI result overall survival ( OS ) comparable historical rate observe conventional myeloablative regimen pediatric population . The preparative regimen result adequate incidence neutrophil platelet engraftment , acceptable rate graft-versus-host disease ( GVHD ) , relapse survival . The pharmacokinetic ( PK ) profile treosulfan child comparable adult previously study .</brief_summary>
	<brief_title>Treosulfan/Fludarabine/Low Dose TBI Preparative Regimen Children With AML/MDS Undergoing Allo HCT</brief_title>
	<detailed_description>The propose study evaluate regimen use treosulfan , fludarabine low-dose TBI child adolescent AML MDS undergo allogeneic HCT . We expect regimen yield lower toxicity least equivalent rate disease control overall survival , compare current standard myeloablative regimen . The primary objective study determine safety preliminary efficacy transplant preparative regimen consist treosulfan , fludarabine low-dose TBI child AML MDS . The primary endpoint overall survival ( OS ) one year . Secondary objective study include : pharmacokinetic ( PK ) profile treosulfan child &lt; 40 kg , non-relapse mortality , disease-free survival , incidence neutrophil platelet engraftment , donor chimerism , acute chronic graft-versus-host disease ( GVHD ) , relapse .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Age &lt; 21 year . 2 . Disease disease status : Acute myeloid leukemia ( AML ) morphologic remission ( define &lt; 5 % blast bone marrow aspirate adequate cellularity perform within 28 day start condition ) . Myelodysplastic syndrome ( MDS ) : Any 2008 WHO classification subtype ( Appendix I ) . RAEB2 patient may proceed directly transplant , may also consider induction chemotherapy transplant . Patients ≥20 % morphologic marrow blast require induction therapy reduce morphologic marrow blast 5 % transplant . 3 . Karnofsky Index Lansky PlayPerformance Scale &gt; 70 % pretransplant evaluation . Karnofsky score must use patient &gt; 16 year age Lansky score patient &lt; 16 year age . 4 . Able give inform consent &gt; 18 year , legal guardian capable give informed consent &lt; 18 year . 5 . Negative pregnancy test ( serum , urine βHCG , test per institutional guideline ) female childbearing potential . 6 . A single previous autologous allogeneic HCT allow long time first second transplant hematopoietic cell infusion le 6 month . 7 . With suitable allogeneic hematopoietic cell donor include , available : HLAidentical relate donor match HLAA , B serologic level minimum DRB1 high resolution molecular typing . A single locus mismatch related donor ( 7/8 match ) permit 8/8 match unrelated donor available . Unrelated volunteer donor match HLAA , B , C DRB1 define high resolution molecular typing . A single HLA antigen allele mismatch ( 7/8 match ) permit . Unrelated cord blood ( UCB ) match recipient minimum 4 6 locus HLAA , B intermediate resolution DRB1 high resolution . Cord blood unit ( ) select use follow criterion : 1 . Unit selection base cryopreserved total nucleated cell ( TNC ) dose match HLAA , B intermediate resolution DRB1 high resolution type . While HLAC antigen/allele level typing consider matching criterion , available , may use optimize unit selection . 2 . Selection two UCB unit require single UCB unit provide sufficient cell dose ( see Table 1 ) . When two UCB unit require per Table 1 , two UCB unit may use approval study chair designee . When two unit select , follow rule apply : The UCB unit least HLA disparity patient , follow large cell dose equivalently match unit , consider unit # 1 ( selection priority 6/6 match &gt; 5/6 match &gt; 4/6 match ) . An additional UCB unit may require achieve require cell dose , outline table . The second unit one closely HLA match patient meet minimum size criterion outline ( i.e . small closely match unit select large less well matched unit long minimum cell dose criterion meet ) . Each UCB unit MUST contain least 1.5 x 10^7 TNC per kilogram recipient weight . 3 ) Other comment cord blood unit selection : Use unlicensed cord blood unit adhere current federal regulatory requirement procurement . Units select base TNC dose HLA matching . A UCB unit 4/6 5/6 mismatch homozygous locus mismatch choose 5/6 unit bidirectional mismatch even latter unit provide large cell dose . This applicable choose unit within give match grade . Within best HLA match grade , unit contain great number cell choose . If two unit equivalent cell dose within match level , choose unit best match high resolution molecular typing , know . Other factor consider : . Within HLA match grade , match DR locus preferable . ii . UCB unit source cord blood bank locate United States prefer . iii . Younger unit prefer old unit , factor equal . 8 . Adequate organ function , define : Pulmonary : FEV1 , FVC , correct DLCO must ≥ 50 % predict pulmonary function test ( PFTs ) . For child unable perform PFTs due age , criterion : evidence dyspnea rest need supplemental oxygen . Renal : GFR estimate updated Schwartz formula ≥ 90/min/1.73 m2 , i.e . height ( cm ) /serum creatinine ( mg/dl ) &gt; 220 . If estimate creatinine clearance &lt; 90 ml/min/1.73 m2 , renal function must measure 24hour creatinine clearance nuclear GFR , must &gt; 70 mL/minute/1.73 m2 Cardiac : Shortening fraction ≥ 27 % echocardiogram radionuclide scan ( MUGA ) ejection fraction ≥ 50 % echocardiogram radionuclide scan ( MUGA ) Hepatic : SGOT ( AST ) SGPT ( ALT ) &lt; 5 x upper limit normal ( ULN ) age ; Conjugated bilirubin &lt; 2.5 mg/dL , unless attributable Gilbert 's Syndrome . 9 . Co enrollment PBMTC ONC 1001 ( CIBMTR 09MRD ) protocol and/or CIBMTR 10CBA protocol ( NMDP cord blood IND ) allow . Coenrollment study experimental therapy administer handled casebycase basis must discuss study chair designee prior enrollment . 1 . Pregnant lactating female ineligible many medication use protocol could harmful unborn child infant . 2 . Patients HIV uncontrolled fungal , bacterial viral infection exclude . Patients history fungal disease induction therapy may proceed significant response antifungal therapy minimal evidence disease remain CT evaluation . 3 . Patients active CNS leukemia active site extramedullary disease time enrollment permit . Note : Those prior history CNS extramedullary disease , active disease time pretransplant workup , eligible . 4 . Patients undergoing course chemotherapy use another investigational drug . 5 . Patients diagnose Fanconi Anemia .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>Treosulfan</keyword>
</DOC>